TELA Bio Appoints Jeffrey Blizard to Board, Strengthening Sales Expertise

TELA Bio

MALVERN, PA — TELA Bio, Inc. (Nasdaq: TELA) announced the appointment of Jeffrey Blizard, Global Head of Surgical Sales at Abiomed, to its Board of Directors. This move, effective June 4, 2024, aims to bolster the company’s sales capabilities during a period of significant growth.

Antony Koblish, co-founder, President, and CEO of TELA Bio, expressed enthusiasm for the new addition. “We are excited to have Jeff join our Board as we continue to develop and optimize our sales force,” he said. “Jeff’s exceptional sales leadership and extensive experience will be a tremendous asset to our Board of Directors.”

Blizard brings a wealth of experience to TELA Bio. Since 2017, he has led global surgical sales at Abiomed, a medical device company within Johnson & Johnson’s MedTech Segment. His tenure at Abiomed is marked by impressive achievements, including growing sales of the Impella heart pump from $16 million to $300 million in seven years. Prior to Abiomed, Blizard held senior sales roles at Medtronic, HeartWare, Intuitive Surgical, and Boston Scientific.

“I am thrilled to join TELA Bio’s Board of Directors during this dynamic period of growth,” said Blizard. “I am confident that my broad range of sales expertise will significantly contribute to TELA’s continued success.”

Blizard’s appointment comes as TELA Bio seeks to expand its market presence and enhance its sales strategies. His track record in scaling sales operations and driving revenue growth positions him as a key contributor to TELA’s objectives. Additionally, Blizard’s experience with advanced medical technologies aligns with TELA Bio’s innovative approach to surgical solutions.

READ:  Omega Flex Declares Quarterly Dividend of $0.34 Per Share
TELA Bio’s Strategic Coup: Elevating Sales Leadership for Market Domination

By enhancing its board with proven sales leadership, TELA Bio aims to strengthen its market position and accelerate growth. Blizard’s insights into sales dynamics and his connections within the medical device industry could open new opportunities for partnerships and market expansion.

Moreover, Blizard’s role extends beyond sales. His involvement in strategic decision-making will likely influence product development and market entry strategies. As healthcare technology evolves, companies like TELA Bio must navigate complex market landscapes. Leadership with deep industry knowledge can provide a competitive edge.

Blizard also serves on the Board of Directors of SANUWAVE Health, Inc., a company specializing in regenerative medicine technologies. His diverse background in medical device sales and leadership across multiple prominent firms adds a multifaceted perspective to TELA Bio’s board.

As TELA Bio continues its growth trajectory, the addition of Jeffrey Blizard to the Board of Directors signifies a strategic move to harness top-tier sales expertise. With his extensive background and proven success, Blizard is poised to contribute significantly to TELA Bio’s mission of advancing surgical innovation and improving patient outcomes.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.